WO2005067460A3 - Epha2 vaccines - Google Patents

Epha2 vaccines Download PDF

Info

Publication number
WO2005067460A3
WO2005067460A3 PCT/US2004/034693 US2004034693W WO2005067460A3 WO 2005067460 A3 WO2005067460 A3 WO 2005067460A3 US 2004034693 W US2004034693 W US 2004034693W WO 2005067460 A3 WO2005067460 A3 WO 2005067460A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
methods
cancer
autologous
antigenic peptides
Prior art date
Application number
PCT/US2004/034693
Other languages
French (fr)
Other versions
WO2005067460A2 (en
Inventor
Michael S Kinch
Original Assignee
Medimmune Inc
Michael S Kinch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc, Michael S Kinch filed Critical Medimmune Inc
Priority to EP04809990A priority Critical patent/EP1732580A4/en
Publication of WO2005067460A2 publication Critical patent/WO2005067460A2/en
Publication of WO2005067460A3 publication Critical patent/WO2005067460A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer, and hyperproliferative diseases involving EphA2-expressing cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of an EphA2 antigenic peptide to elicit an immune response against the EphA2-expressing cells. In other embodiments, the methods of the invention entail the use of an EphA2 expression vehicle, such as a naked nucleic acid or viral vector. In yet other embodiments, the methods of the invention comprise the use of adoptive immunotherapy with autologous or non-autologous antigen presenting cells that are sensitized with one or more EphA2 antigenic peptides. The invention also provides pharmaceutical compositions comprising one or more EphA2 antigenic peptides, expression vehicles or antigen-presenting cells of the invention either alone or in combination with one or more other agents useful for cancer therapy.
PCT/US2004/034693 2003-12-24 2004-10-15 Epha2 vaccines WO2005067460A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04809990A EP1732580A4 (en) 2003-12-24 2004-10-15 Epha2 vaccines

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US53269603P 2003-12-24 2003-12-24
US60/532,696 2003-12-24
US60258804P 2004-08-18 2004-08-18
US60/602,588 2004-08-18
US61554804P 2004-10-01 2004-10-01
US60/615,548 2004-10-01
US61756404P 2004-10-07 2004-10-07
US60/617,564 2004-10-07

Publications (2)

Publication Number Publication Date
WO2005067460A2 WO2005067460A2 (en) 2005-07-28
WO2005067460A3 true WO2005067460A3 (en) 2006-10-26

Family

ID=34799812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/034693 WO2005067460A2 (en) 2003-12-24 2004-10-15 Epha2 vaccines

Country Status (2)

Country Link
EP (1) EP1732580A4 (en)
WO (1) WO2005067460A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691393B2 (en) 2003-02-06 2010-04-06 Anza Therapeutics, Inc. Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229543A1 (en) * 2003-04-11 2004-10-28 Medimmune, Llc EphA2 and non-neoplastic hyperproliferative cell disorders
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
CN101755044B (en) 2007-05-18 2014-06-11 米迪缪尼有限公司 Preservation of bioactive materials by freeze dried foam
RU2525133C2 (en) 2007-08-30 2014-08-10 Дайити Санкио Компани, Лимитед Antibody to epha2
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
ES2722799T3 (en) * 2010-08-24 2019-08-16 Univ Pittsburgh Commonwealth Sys Higher Education Brain cancer vaccines based on the interleukin-13 receptor alpha 2 peptide
CA2990864A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
WO2017070619A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
EP3589297A1 (en) 2017-03-03 2020-01-08 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
CN111770789B (en) 2017-12-29 2023-05-05 塞鲁斯公司 System and method for processing biological fluids
MX2021015653A (en) 2019-06-22 2022-04-11 Cerus Corp Biological fluid treatment systems.
EP3991179A1 (en) 2019-06-28 2022-05-04 Cerus Corporation System and methods for implementing a biological fluid treatment device

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243228B2 (en) * 2002-05-10 2009-03-26 Medimmune, Llc EphA2 monoclonal antibodies and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUXBURY ET AL.: "Ligation of EphA2 by Ephrin A1-Fc Inhibits Pancreatic Adenocarcinoma Cellular Invasiveness", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 320, no. 4, August 2004 (2004-08-01), pages 1096 - 1102, XP027194341, DOI: doi:10.1016/j.bbrc.2004.06.054 *
HATANA ET AL.: "EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines", NEOPLASIA, vol. 7, no. 8, August 2005 (2005-08-01), pages 717 - 722, XP008076099, DOI: doi:10.1593/neo.05277 *
HATANA ET AL: "Vaccination with EphA2-Derived T Cell-Epitopes Promotes Immunity Against Both EphA2-Expression and EphA2-Negative Tumors", J. TRANSL. MED., vol. 2, no. 1, November 2004 (2004-11-01), pages 40, XP021018960, DOI: doi:10.1186/1479-5876-2-40 *
WYKOSKY ET AL.: "EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme", MOL. CANCER RES., vol. 3, no. 10, October 2005 (2005-10-01), pages 541 - 551, XP008076096, DOI: doi:10.1158/1541-7786.MCR-05-0056 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691393B2 (en) 2003-02-06 2010-04-06 Anza Therapeutics, Inc. Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the Listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7927606B2 (en) 2003-02-06 2011-04-19 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof

Also Published As

Publication number Publication date
EP1732580A4 (en) 2008-01-23
EP1732580A2 (en) 2006-12-20
WO2005067460A2 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
WO2005067460A3 (en) Epha2 vaccines
KR20210120066A (en) Pharmaceutical composition for the treatment of pancreatic cancer
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
WO2010037514A3 (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2011113819A3 (en) Diagnosis and treatment of cancer based on avl9
SG10201807588TA (en) Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
MX2010001086A (en) Novel immunotherapy against neuronal and brain tumors.
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
DK1806359T3 (en) Tumor-associated peptides promiscuously bound to human leukocyte antigen (HLA) class II molecules
UA97095C2 (en) Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
EA201071297A1 (en) NEW AND EFFECTIVE PEPTIDES OF THE MHC II CLASS RECEIVED FROM Survivin
DE69839273D1 (en) CANCER IMMUNOTHERAPY WITH SEMI-ALLOGENIC CELLS
WO2005007673A3 (en) Immunogenic peptides
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2003093298A3 (en) Immunogenic peptides
WO2003086041A3 (en) Binding agents and their use in targeting tumor cells
Smith et al. Immunotherapy in cancer treatment
MY127452A (en) Vaccines.
La Cava Modulation of autoimmunity with artificial peptides
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2011090266A3 (en) Novel tumor antigen protein agr2 and tumor antigenic peptide thereof
EA202190186A1 (en) PEPTIDES, COMBINATIONS OF PEPTIDES AND CELL-BASED MEDICINES FOR USE IN IMMUNOTHERAPY OF BLADDER CANCER AND OTHER TYPES OF CANCER
EA202191120A3 (en) PEPTIDES AND THEIR COMBINATIONS FOR USE IN CANCER IMMUNOTHERAPY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2004809990

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2004809990

Country of ref document: EP